TY  - GEN
AU  - Janku,Filip
AU  - Hong,David S
AU  - Fu,Siqing
AU  - Piha-Paul,Sarina A
AU  - Naing,Aung
AU  - Falchook,Gerald S
AU  - Tsimberidou,Apostolia M
AU  - Stepanek,Vanda M
AU  - Moulder,Stacy L
AU  - Lee,J Jack
AU  - Luthra,Rajyalakshmi
AU  - Zinner,Ralph G
AU  - Broaddus,Russell R
AU  - Wheler,Jennifer J
AU  - Kurzrock,Razelle
TI  - Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
SN  - 2211-1247
PY  - 2014///0926
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Colorectal Neoplasms
KW  - drug therapy
KW  - Female
KW  - Humans
KW  - Male
KW  - Melanoma
KW  - Middle Aged
KW  - Mutation
KW  - Ovarian Neoplasms
KW  - PTEN Phosphohydrolase
KW  - genetics
KW  - Phosphatidylinositol 3-Kinases
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Protein Kinase Inhibitors
KW  - pharmacology
KW  - Proto-Oncogene Proteins c-akt
KW  - antagonists & inhibitors
KW  - TOR Serine-Threonine Kinases
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
UR  - https://doi.org/10.1016/j.celrep.2013.12.035
ER  -